Loading organizations...
§ Venture Capital · Shanghai, Shanghai, China
Healthcare venture capital firm investing in biopharmaceuticals, medical devices, and diagnostics, providing capital and active support.
Grand Mount Capital (GMC) is a healthcare venture capital firm that invests in biopharmaceuticals, medical devices, and diagnostics. The firm provides capital alongside active support, including market access, regulatory guidance, and strategic collaborations, to its portfolio companies. GMC's investment strategy is funded by state-owned capital and investment professionals, aiming for returns through portfolio company growth and successful exits. The firm's scale, including assets under management or specific funding amounts, is not publicly disclosed. President Shanshan Zhang leads the firm, which works closely with listed companies and healthcare conglomerates to enhance portfolio value, and has publicly commented on the biopharmaceutical sector, notably regarding Sanyou Biopharmaceuticals' Series B financing. Grand Mount Capital was established in 2019 by state-owned capital and investment professionals.
Grand Mount Capital has 1 tracked investment across 1 company. The latest tracked deal is $62.0M Series B in Neurophth Therapeutics in February 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 9, 2021 | Neurophth Therapeutics | $62.0M Series B | Lane Zhao | Harvest Capital, Trency GU, Northern Light Venture Capital, Oriza Holdings |